High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib

High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib

Abstract Tyrosine kinase inhibitor (TKI) can help to increase the survival time in chronic myeloid leukemia (CML) patients; however, the risk of secondary malignancies due to TKIs is a growing concern. Only few reports showed clinical course of patients who developed lymphoma during TKI therapies. H...

Full description

Bibliographic Details
Main Authors: Teruhito Takakuwa, Ryota Sakai, Shiro Koh, Hiroshi Okamura, Satoru Nanno, Yasuhiro Nakashima, Takahiko Nakane, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Clinical Case Reports
Subjects:
bosutinib
chronic myeloid leukemia
high‐grade B‐cell lymphoma
second malignancy
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/ccr3.3770

Internet

https://doi.org/10.1002/ccr3.3770

Similar Items